#novo-nordisk

[ follow ]
#pharmaceutical-industry

Denmark gets Novo Nordisk to lower Ozempic prices

Sanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.

Novo Nordisk's Wegovy sales jump on international rollouts

Wegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.

Skinny jabs': weight-loss drugs set for new boom as generic versions emerge

The introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.

Europe's most valuable company Novo Nordisk reports a slight increase in profits

Novo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.

Denmark gets Novo Nordisk to lower Ozempic prices

Sanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.

Novo Nordisk's Wegovy sales jump on international rollouts

Wegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.

Skinny jabs': weight-loss drugs set for new boom as generic versions emerge

The introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.

Europe's most valuable company Novo Nordisk reports a slight increase in profits

Novo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
morepharmaceutical-industry
#wegovy

New Study Finds Wegovy Reduces COVID Death Risk By 33 Percent

Novo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.

'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearing

The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.

Ozempic and Wegovy linked to rare vision loss

Novo Nordisk's drugs Ozempic and Wegovy linked to higher risk of vision loss.

The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?

The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.
Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.

Woman Says Her Colon Had to Be Removed After Taking Ozempic

A woman is suing Novo Nordisk after losing her colon due to complications she claims were caused by their weight loss and diabetes medications.

Bernie Sanders grills Ozempic maker over high prices

Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.

New Study Finds Wegovy Reduces COVID Death Risk By 33 Percent

Novo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.

'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearing

The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.

Ozempic and Wegovy linked to rare vision loss

Novo Nordisk's drugs Ozempic and Wegovy linked to higher risk of vision loss.

The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?

The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.
Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.

Woman Says Her Colon Had to Be Removed After Taking Ozempic

A woman is suing Novo Nordisk after losing her colon due to complications she claims were caused by their weight loss and diabetes medications.

Bernie Sanders grills Ozempic maker over high prices

Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
morewegovy
#economic-growth

Ozempic's biggest side effect: Turning Denmark into a 'pharmastate'?

Denmark's economy heavily relies on Novo Nordisk and its diabetes medication Ozempic for growth and job creation.

Half of Denmark's GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict

Novo Nordisk is pivotal for Denmark's GDP growth in 2024, surpassing its Nordic peers.

Novo Nordisk's market value of $570 billion is more than Denmark's annual GDP

Danish PM defends economy's resilience amid concerns of over-reliance on Novo Nordisk.

Danish town where Ozempic is made has highest rates of overweight children in Denmark

Novo Nordisk's investment success is overshadowed by local socio-economic challenges in Kalundborg, including obesity and inadequate public services.

Ozempic's biggest side effect: Turning Denmark into a 'pharmastate'?

Denmark's economy heavily relies on Novo Nordisk and its diabetes medication Ozempic for growth and job creation.

Half of Denmark's GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict

Novo Nordisk is pivotal for Denmark's GDP growth in 2024, surpassing its Nordic peers.

Novo Nordisk's market value of $570 billion is more than Denmark's annual GDP

Danish PM defends economy's resilience amid concerns of over-reliance on Novo Nordisk.

Danish town where Ozempic is made has highest rates of overweight children in Denmark

Novo Nordisk's investment success is overshadowed by local socio-economic challenges in Kalundborg, including obesity and inadequate public services.
moreeconomic-growth
#weight-loss-drugs

How little Denmark got homegrown giant Novo Nordisk to lower Ozempic prices

Pharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.

Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds

Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.

Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Novo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.

Inside the Ozempic factory: How a $430 billion Danish pharma giant feeds America's appetite for weight-loss drugs

Denmark has one of the lowest obesity rates in Europe, but it has been on the rise.
Novo Nordisk, a Danish pharmaceutical company, has developed drugs that can help regulate blood sugar and aid in weight loss.

Wegovy Approved to Cut Heart Disease and Stroke Risk

Weight loss drugs approved for heart health benefits
Semaglutide linked to cardiovascular risk reduction

Novo Nordisk's record-breaking growth highlights 'insatiable demand' for weight loss drugs

Novo Nordisk achieved a 20-year high in revenue growth rate, beating estimates for FY2023 revenue and earnings.
The growth is not demand constrained but production capacity constrained, with an insatiable demand for weight loss drugs.

How little Denmark got homegrown giant Novo Nordisk to lower Ozempic prices

Pharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.

Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds

Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.

Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Novo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.

Inside the Ozempic factory: How a $430 billion Danish pharma giant feeds America's appetite for weight-loss drugs

Denmark has one of the lowest obesity rates in Europe, but it has been on the rise.
Novo Nordisk, a Danish pharmaceutical company, has developed drugs that can help regulate blood sugar and aid in weight loss.

Wegovy Approved to Cut Heart Disease and Stroke Risk

Weight loss drugs approved for heart health benefits
Semaglutide linked to cardiovascular risk reduction

Novo Nordisk's record-breaking growth highlights 'insatiable demand' for weight loss drugs

Novo Nordisk achieved a 20-year high in revenue growth rate, beating estimates for FY2023 revenue and earnings.
The growth is not demand constrained but production capacity constrained, with an insatiable demand for weight loss drugs.
moreweight-loss-drugs
#senate-hearing

Analysts say market forces will lower cost of obesity drugs

Congressional pressure likely won't significantly affect the pricing of Novo Nordisk's drugs, Ozempic and Wegovy.

Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEO

The U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.

Analysts say market forces will lower cost of obesity drugs

Congressional pressure likely won't significantly affect the pricing of Novo Nordisk's drugs, Ozempic and Wegovy.

Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEO

The U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.
moresenate-hearing

Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects

Novo Nordisk's new weight loss drug monlunabant shows promising results but raises concerns due to increased risk of psychiatric side effects compared to placebo.
#ozempic

Forget the shot. A weight loss pill saw promising results in Phase 1 testing

Amycretin, a new pill, could offer a convenient weight loss alternative to Ozempic, showing potential for significant weight loss within three months.

Ozempic 'very likely' to have price slashed

Ozempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.

Tracy Morgan Says He Actually Managed to Gain Weight on Ozempic With Superhuman Eating Abilities

Tracy Morgan claims to have out-eaten Ozempic, gaining 40 pounds despite its appetite-limiting effects.
Ozempic from Novo Nordisk is gaining popularity for weight loss treatment among celebrities, despite concerns about its long-term effectiveness and safety.

Forget the shot. A weight loss pill saw promising results in Phase 1 testing

Amycretin, a new pill, could offer a convenient weight loss alternative to Ozempic, showing potential for significant weight loss within three months.

Ozempic 'very likely' to have price slashed

Ozempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.

Tracy Morgan Says He Actually Managed to Gain Weight on Ozempic With Superhuman Eating Abilities

Tracy Morgan claims to have out-eaten Ozempic, gaining 40 pounds despite its appetite-limiting effects.
Ozempic from Novo Nordisk is gaining popularity for weight loss treatment among celebrities, despite concerns about its long-term effectiveness and safety.
moreozempic
#obesity-treatment

Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial

Novo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.

Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial

Novo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.

Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial

Novo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.

Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial

Novo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.
moreobesity-treatment

The next big market for weight-loss drugs: children

Novo Nordisk's Saxenda can significantly reduce children's BMI, showing potential for FDA approval in a market with currently no approved obesity medications for children.

Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions

Many patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.

Sen. Bernie Sanders launches Senate investigation into 'high' pricing of Ozempic, Wegovy

Sen. Bernie Sanders investigating high drug prices for Ozempic and Wegovy.

Senate Committee Investigates Ozempic and Wegovy Costs

The Senate Committee is investigating Novo Nordisk's high prices for Ozempic and Wegovy medications, urging the company to consider lowering costs for better accessibility.
#nvidia

The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project

Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.

Denmark's new Nvidia AI supercomputer will come online this year

Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.

The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project

Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.

Denmark's new Nvidia AI supercomputer will come online this year

Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
morenvidia

Study shows no evidence of suicidal thoughts caused by Ozempic, Wegovy

A large U.S. study found no evidence of a link between Novo Nordisk's Ozempic and Wegovy and an increase in suicidal thoughts.
The study found that semaglutide, the active ingredient in Ozempic and Wegovy, actually had a lower risk of new and recurrent suicidal thoughts compared to other medications for weight loss or diabetes.

Five hundred new jobs coming in Chartres, south of Paris

Danish pharmaceutical giant Novo Nordisk is investing €2.1 billion in a French production site to expand the capacity and manufacturing of its anti-obesity drug.
Novo Nordisk's Semaglutide medication, originally meant for diabetes, is also effective against obesity and has massive global potential.
Goldman Sachs predicts that the global market for anti-obesity medication could reach $100 billion by 2030.

Ozempic and Wegovy could soon be challenged by China's generic competitors

Intensifying competition in Chinese market for Novo Nordisk's diabetes drug Ozempic and weight loss treatment Wegovy.
[ Load more ]